Carol Ann Deno, RPH | |
501 North Nichols St., Big Piney, WY 83113 | |
(307) 276-3499 | |
(307) 276-3518 |
Full Name | Carol Ann Deno |
---|---|
Gender | Female |
Speciality | Pharmacist |
Location | 501 North Nichols St., Big Piney, Wyoming |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1265583082 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 1892 (Wyoming) | Primary |
Mailing Address | Practice Location Address |
---|---|
Carol Ann Deno, RPH Po Box 4553, Marbleton, WY 83113-4553 Ph: (307) 276-3499 | Carol Ann Deno, RPH 501 North Nichols St., Big Piney, WY 83113 Ph: (307) 276-3499 |
News Archive
A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the "third-generation" pills are doubly harmful than the older versions.
Researchers at Karolinska Institutet in Sweden have managed to synthesise lung surfactant, a drug used in the care of preterm babies, by mimicking the production of spider silk.
CitiusTech announced today that BI-Clinical Framework 10.3 is 2011/2012 compliant and was certified as an EHR Module on May 12, 2011 by the Certification Commission for Health Information Technology, an ONC-ATCB, in accordance with the applicable Eligible Hospital certification criteria adopted by the Secretary of Health and Human Services.
It is time to reassess mental disorders, recognizing that these are disorders of brain circuits likely caused by development processes, according to a commentary in the May 19 issue of JAMA, a theme issue on mental health.
A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.
› Verified 4 days ago